Organisation paid for research Program year 2025 Source: CMS Open Payments

Arkansas Research Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$1,779,433

191 payments

Through program year 2025, Arkansas Research Trials LLC is reported as receiving $1,779,433 in research payments, across 191 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $303,264 41
2024 Research $406,781 47
2023 Research $242,934 36
2022 Research $205,957 27
2021 Research $463,212 26
2020 Research $157,285 14

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $1,051,010 45 payments
  2. AbbVie, Inc. $455,408 104 payments
  3. Genzyme Corporation $103,842 11 payments
  4. Amgen Inc. $88,653 8 payments
  5. Pfizer Inc. $44,525 7 payments
  6. Galderma Laboratories, L.P. $23,442 6 payments
  7. LEO Pharma AS $9,565 9 payments
  8. Horizon Therapeutics plc $2,989 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $253,566 5 payments
  2. An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $153,036 2 payments
  3. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $140,946 15 payments
  4. A Phase 2B, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa $103,604 2 payments
  5. Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis $95,885 2 payments
  6. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $78,197 2 payments
  7. M18-891 $77,500 8 payments
  8. A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) $75,232 5 payments
  9. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $74,234 1 payment
  10. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $63,075 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record